Hyejin Lee

Hyejin Lee

Auto-generated profile, based on publicly available information

Hyejin Lee

Department of Biological Sciences, Sookmyung Women’s University, Seoul, Korea

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2025 in Organoid
Verified
Journal Article
Open access
PDF file
CLChaeyoun Lee
Chaeyoun Lee
YCYoonseo Choi
Yoonseo Choi
HLHyejin Lee
Hyejin Lee
BLByung-Chul Lee
Byung-Chul Lee
Hematopoietic stem cell transplantation (HSCT) has long served as an unparalleled therapeutic option for numerous hematologic malignancies and genetic disorders. However, the efficacy of HSCT is often limited by suboptimal homing of transplanted stem cells to the bone marrow (BM) niche and insufficient long-term engraftment. Despite the need for effective methods to predict clinical outcomes, a suitable model system remains lacking. In this review, we first examine the biological factors that govern hematopoietic stem cell (HSC) homing and niche interactions, including key chemokine–receptor axes (such as CXCR4–CXCL12) and regulatory molecules that facilitate long-term HSC quiescence and repopulation. We then explore how CRISPR-based gene editing technologies are leveraged to modify HSCs for improved clinical outcomes, while addressing the challenges of DNA damage responses and off-target effects associated with editing. Most importantly, we highlight emerging BM organoid (BMO) systems as next-generation 3-dimensional culture models that recapitulate the human BM microenvironment. BMOs represent a promising platform for preclinical testing of gene-edited HSCs and for investigating human-specific HSC–niche interactions beyond animal models. By integrating gene-edited HSCs with organoid models, researchers can more accurately evaluate HSC homing and engraftment in a precisely mimicked, human-like environment. We also emphasize the potential of combining gene editing with BMO technologies to advance personalized HSCT and pave the way for safer, more effective transplantation procedures. Despite their promise, current BMOs exhibit limitations such as incomplete tissue recapitulation, lack of vascularization, batch variability, and limited long-term stability. Addressing all these challenges will be essential for increasing their physiological relevance and translational potential.